AIMT: Aimmune Therapeutics Inc - Earnings Announcements. Stay up to date with lastest Earnings Announcements for Aimmune Therapeutics Inc from Zacks Investment Research AIMT: Aimmune Therapeutics Inc - Full Company Report. Get the latest Full Company Report for Aimmune Therapeutics Inc from Zacks Investment Research Get breaking news and analysis on Aimmune Therapeutics, Inc. (AIMT) stock, price quote and chart, trading and investing tools. at Zacks.com (Feb 21, 2020) AIMT: Aimmune Therapeutics, Inc. broker recommendations. Get the latest broker recommendations from Zacks Investment Research. Is the Options Market Predicting a Spike in Aimmune (AIMT) Stock? 02/21/20-8:01AM EST Zacks Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. Full Company Report for AIMT.
AIMT stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Wellington Management Group LLP, Bank of New York Mellon Corp, Victory Capital Management Inc., Victory Capital Management Inc., Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, and Fiera Capital Corp. Company insiders
Aimmune Therapeutics (NASDAQ:AIMT) Downgraded by Zacks ... AIMT traded up $0.16 during midday trading on Friday, reaching $16.02. 1,481,999 shares of the company’s stock traded hands, compared to its average volume of 2,023,825. The firm has a fifty day moving average of $17.74 and a two-hundred day moving average of $26.10. The stock has a market capitalization of $993.93 million, a price-to-earnings ratio of -4.04 and a beta of 0.92. Is the Options Market Predicting a Spike in Aimmune (AIMT ... Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Aimmune Therapeutics, Inc. (AIMT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research Aimmune Therapeutics (NASDAQ:AIMT) Lifted to Buy at Zacks ...
Aimmune Therapeutics, Inc. (AIMT) Stock Price, Quote ...
Aimmune Stock Halted as FDA Considers Peanut Allergy Treatment. By Tony Owusu. Sep 13, 2019 10:50 AM EDT. JIM CRAMER. What's It Worth to You?: Cramer's 'Mad Money' Recap. By Scott Rutt. Zacks: Brokerages Expect Aimmune Therapeutics Inc (AIMT ... Wall Street brokerages expect that Aimmune Therapeutics Inc (NASDAQ:AIMT) will announce earnings per share of ($0.90) for the current quarter, Zacks reports. Zero analysts have issued estimates for Aimmune Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.84) and the lowest estimate coming in at ($1.00). Aimmune Therapeutics posted earnings per share of […] Aimmune Therapeutics: 1Q Earnings Snapshot - NewsTimes May 11, 2020 Get the latest Aimmune Therapeutics, Inc. AIMT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Aimmune Therapeutics, Inc. - AIMT - Stock Price Today - Zacks Quote Overview
AIMT | Complete Aimmune Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Jun 13, 2019
Find real-time AIMT - Aimmune Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.
AIMT: Get the latest Aimmune Therapeutics stock price and detailed information including AIMT news, historical charts and realtime prices. Aimmune Therapeutics, Inc. (AIMT) Stock Analysis & News ... at Zacks.com (May 11, 2020) Is the Options Market Predicting a Spike in Aimmune (AIMT) Stock? at Zacks.com (Feb 21, 2020) (AIMT) stock, price quote and chart, trading and investing tools. Aimmune Therapeutics (NASDAQ:AIMT) Upgraded to “Buy” by ...